This paper is only available as a PDF. To read, Please Download here.
Abstract
In a randomized, open-label, controlled, multicentre study, the clinical and bacteriological efficacy, safety and tolerability of oral gemifloxacin (320 mg once daily, 5 days) was compared with sequential intravenous (i.v.) ceftriaxone (1 g once daily, maximum 3 days) followed by oral cefuroxime axetil (500 mg twice daily, maximum 7 days) in adult hospitalized patients with acute exacerbations of chronic bronchitis (AECB) (n = 274). The clinical success rates at follow-up (21–28 days post-therapy) in the clinical per-protocol population (the primary endpoint) were 86.8% (105/121) for gemifloxacin vs. 81.3% (91/112) for ceftriaxone/cefuroxime (treatment difference = 5.5, 95% CI −3.9, 14.9). The corresponding clinical results in the clinical intention-to-treat (ITT) population were 82.6% (114/138) vs. 72.1% (98/136), respectively (treatment difference = 10.5, 95% CI 0.7, 20.4). Thus, gemifloxacin had significantly higher clinical success rates than ceftriaxone/cefuroxime. The median time to discharge was 9 days in the gemifloxacin group vs. 11 days in the ceftriaxone/cefuroxime group (P = 0.04, Wilcoxon test). At follow-up, 120/138 (87.0%) gemifloxacin-treated patients had been discharged from hospital, compared with 111/136 (81.6%) ceftriaxone/cefuroxime-treated patients in the clinical ITT population. Both treatments were generally well tolerated and there was no significant difference between the treatment groups in the incidence or type of adverse events reported. A 5-day course of oral gemifloxacin was shown by this study to be at least equivalent to sequential i.v. ceftriaxone/cefuroxime axetil (for up to 10 days) in patients with AECB who require hospital treatment.
Keywords
References
REFERENCES
- Epidemiology and treatment of chronic bronchitis and its exacerbations.Chest. 1995; 108: 43S-52S
- Treatment costs of acute exacerbations of chronic bronchitis.Clin Ther. 1999; 21: 576-591
- Acute infective exacerbations of chronic bronchitis: study of outcome by clinical parameters.Q J Med. 1995; 88: 61-68
- Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis.J Antimicrob Chemother. 2000; 45: 19-24
- Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.J Antimicrob Chemother. 2001; 47: 129-140
- Burden and cost of LRTI: a methodologic overview.Infect Med. 1998; 15: 26-31
- Cost benefits from improving clinical outcome.Infect Med. 1998; 15: 61-67
- Sequential antimicrobial therapy—the role of quinolones.J Antimicrob Chemother. 1997; 39: 441-446
- Intravascular catheter associated sepsis: a common problem. The Australian Study on Intravascular Catheter Associated Sepsis.Med J Aust. 1994; 161: 374-378
- Sequential therapy in the hospital management of lower respiratory infections.Am J Med. 1995; 99: 14S-19S
- Guidelines for the treatment of acute exacerbations of chronic bronchitis.Chest. 1997; 112: 310S-313S
- How do we achieve cost-effective options in lower respiratory tract infection therapy?.Chest. 1998; 113: 205S-210S
- A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America.Antimicrob Agents Chemother. 2000; 44: 3008-3011
- Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.N Engl J Med. 1999; 341: 233-239
- Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis.J Chemother. 2000; 12: 314-325
- Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.J Chemother. 2001; 13: 288-298
- A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.Clin Ther. 2002; 24: 639-652
- Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of lower respiratory tract infections.Int J Antimicrob Agents Chemother. 2001; 18: 19-27
- Sequential therapy with cefuroxime followed by cefuroxime axetil in acute exacerbations of chronic bronchitis.J Antimicrob Chemother. 1997; 40: 863-871
- Antimicrobial practice: sequential therapy with intravenous and oral cephalosporins.J Antimicrob Chemother. 1994; 33: 169-177
- Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A4. NCCLS, Wayne1997
- Performance Standards for Antimicrobial Disk Susceptibility Tests; Eighth Informational Supplement. Approved Standard M100-S8. NCCLS, Wayne1998
- Measurement of the QT interval and the risk associated with QTc interval prolongation: a review.Am J Cardiol. 1993; 72: 23B-25B
- An assessment of hidden and total antibiotic costs of four parenteral cephalosporins.PharmacoEconomics. 1995; 8: 541-550
- Clinical failures: the tip of the iceberg?.Resp Med. 2001; 95: S5-S11
- Infectious complications with respiratory pathogens despite ciprofloxacin therapy.N Engl J Med. 1991; 325: 520-521
- Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.J Antimicrob Chemother. 1999; 43: 83-90
- Comparative efficacy of gemifloxacin (SB-265805) against experimental respiratory tract infection in rats caused by ciprofloxacin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae.Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 26 29, 1999; : 76
Cupo, M, Pypstra, R, Young, C, Safety of gemifloxacin in adult patients with respiratory and urinary tract infections, Seventh Conference of the Federation of Infection Societies, 29 November–1 December 2000
Article info
Publication history
Accepted:
August 20,
2002
Received:
April 8,
2002
Identification
Copyright
© 2003 Elsevier Science Ltd. Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
